Clinical Trial

A Prospective Observational Study on Efficacy of TARE for Early Stage HCC

Study acronym: KURE-YTT-HCC
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the current study is to analyze treatment outcomes (best target lesion response, overall survival, time to target lesion progression, time to overall progression, and treatment-related adverse event) using prospectively collected clinical and imaging data in patients with BCLC 0 or A HCCs treated with TheraSphere® in four large-volume hospitals from Korea. The results will pave the way for expanding 90Y-TARE indication and refining reimbursement guidelines, and provide baseline data for possible subsequent future studies.
Trial Details
NCT Number NCT07278102
Lead Sponsor Seoul National University Hospital
Collaborators: National Cancer Center, Korea, Severance Hospital, Samsung Medical Center
Conditions Radioembolization, Hepatocellular Carcinoma (HCC), Early Stage
Enrollment 200 participants
Start Date 2022-03-28
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-11